Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Palbociclib

36757007-48d8-5668-beb9-e5ce711939eb · FDA Approved · targets CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2

Palbociclib

MeasuredReference

Palbociclib targets CDK4_CYCLIN_D3, CDK4_CYCLIN_D1, CDK6_CYCLIN_D1. Strongest hallmark effect: proliferation.

Primary targets

CDK4_CYCLIN_D3CDK4_CYCLIN_D1CDK6_CYCLIN_D1CDK6_CYCLIN_D3CLK1

Top hallmarks

  • proliferation1.9k
  • evading apoptosis1.6k
  • tumor promoting inflammation1.5k

Top pathways disrupted

  • e2f targets3.6k
  • g2m checkpoint3.2k
  • pi3k akt mtor signaling2.9k

Resistance landscape — Palbociclib

MeasuredReference

No variant annotations found on Palbociclib's top targets.

No variant annotations on Palbociclib's top targets.
Open in new tab